Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) & Turnstone Biologics (NASDAQ:TSBX) Financial Comparison

Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Turnstone Biologics (NASDAQ:TSBX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Quantum Genomics Société Anonyme and Turnstone Biologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Genomics Société Anonyme	0	0	0	0	0.00
Turnstone Biologics	1	0	1	0	2.00

Turnstone Biologics has a consensus price target of $2.13, indicating a potential upside of 370.13%. Given Turnstone Biologics’ stronger consensus rating and higher probable upside, analysts clearly believe Turnstone Biologics is more favorable than Quantum Genomics Société Anonyme.

Profitability

This table compares Quantum Genomics Société Anonyme and Turnstone Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Genomics Société Anonyme	N/A	N/A	N/A
Turnstone Biologics	N/A	-105.99%	-87.27%

Insider and Institutional Ownership

52.5% of Turnstone Biologics shares are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Quantum Genomics Société Anonyme and Turnstone Biologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A
Turnstone Biologics	$19.31 million	0.54	-$55.20 million	($3.24)	-0.14

Quantum Genomics Société Anonyme has higher earnings, but lower revenue than Turnstone Biologics.

Volatility and Risk

Quantum Genomics Société Anonyme has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.

Summary

Turnstone Biologics beats Quantum Genomics Société Anonyme on 7 of the 9 factors compared between the two stocks.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.